CV 9201
Alternative Names: CV-9201Latest Information Update: 04 Oct 2015
At a glance
- Originator CureVac
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 04 Oct 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer in Switzerland and Germany (Intradermal)
- 07 Nov 2011 Immunogenicity & adverse events data from a phase I/IIa trial in Non-small cell lung cancer released by CureVac
- 04 Mar 2011 CureVac completes enrolment in the phase II part of a phase I/II trial for Non-small cell lung cancer in Germany and Switzerland (NCT00923312)